嵌合抗原受体
医学
靶向治疗
细胞疗法
抗原
耐火材料(行星科学)
免疫学
肿瘤科
T细胞
癌症研究
细胞
内科学
癌症
免疫系统
生物
天体生物学
遗传学
作者
Bailu Xie,Zhengdong Li,Jianfeng Zhou,Wen Wang
出处
期刊:Cancers
[MDPI AG]
日期:2022-06-30
卷期号:14 (13): 3230-3230
被引量:35
标识
DOI:10.3390/cancers14133230
摘要
Single-targeted chimeric antigen receptor (CAR) T cells tremendously improve outcomes for patients with relapsed/refractory hematological malignancies and are considered a breakthrough therapy. However, over half of treated patients experience relapse or refractory disease, with antigen escape being one of the main contributing mechanisms. Dual-targeting CAR T-cell therapy is being developed to minimize the risk of relapse or refractory disease. Preclinical and clinical data on five categories of dual-targeting CAR T-cell therapies and approximately fifty studies were summarized to offer insights and support the development of dual-targeting CAR T-cell therapy for hematological malignancies. The clinical efficacy (durability and survival) is validated and the safety profiles of dual-targeting CAR T-cell therapy are acceptable, although there is still room for improvement in the bispecific CAR structure. It is one of the best approaches to optimize the bispecific CAR structure by boosting T-cell transduction efficiency and leveraging evidence from preclinical activity and clinical efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI